Floatz logo

Dr Cysteamine Bitartrate

Nonalcoholic Fatty Liver Disease (NAFLD)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Phase 2/3Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

140 Active assets in the Nonalcoholic Fatty Liver Disease (NAFLD) cohort.

Asset / SponsorPhaseRating
Dapagliflozin
Post Graduate Institute of Medical Education and Research, Chandigarh
Phase 4BBB
Empagliflozin
Justin Ryder
Phase 4BBB
Exenatide
Fudan University
Phase 4BBB
Metformin
Xiqiao Zhou
Phase 4BBB
Pioglitazone
Badr University
Phase 4BBB

View all 50 →

Same molecule, other indications

Dr Cysteamine Bitartrate is also rated in:

cystic fibrosisDormant
B
Indicative ·
58 / 100
View asset →
Huntington diseaseDormant
B
Indicative ·
57 / 100
View asset →
fatty liver diseaseDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →